{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:39:47Z","timestamp":1787614787299,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T00:00:00Z","timestamp":1377820800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T00:00:00Z","timestamp":1377820800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1038\/leu.2013.253","type":"journal-article","created":{"date-parts":[[2013,8,30]],"date-time":"2013-08-30T06:35:08Z","timestamp":1377844508000},"page":"658-665","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease"],"prefix":"10.1038","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9325-432X","authenticated-orcid":false,"given":"V","family":"Bachanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D I","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M-J","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M D","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Arellano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A S","family":"Artz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-Y","family":"Cahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-B","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E A","family":"Copelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W R","family":"Drobyski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R P","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J P","family":"Greer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G A","family":"Hale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Kebriaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H M","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I D","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V A","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J L","family":"Liesveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Litzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A W","family":"Loren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Norkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Oran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Pidala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B N","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Vij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E K","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P H","family":"Wiernik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D J","family":"Weisdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,8,30]]},"reference":[{"key":"BFleu2013253_CR1","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","volume":"109","author":"AV Moorman","year":"2007","unstructured":"Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007; 109: 3189\u20133197.","journal-title":"Blood"},{"key":"BFleu2013253_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/leu.2010.228","volume":"25","author":"S Mizuta","year":"2011","unstructured":"Mizuta S, Matsuo K, Yagasaki F, Yujiri T, Hatta Y, Kimura Y et al. Pre-transplant imatinib-based therapy improves the outcome of allogeneic hematopoietic stem cell transplantation for BCR-ABL-positive acute lymphoblastic leukemia. Leukemia 2011; 25: 41\u201347.","journal-title":"Leukemia"},{"key":"BFleu2013253_CR3","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1002\/cncr.22631","volume":"109","author":"OG Ottmann","year":"2007","unstructured":"Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Duhrsen U et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer 2007; 109: 2068\u20132076.","journal-title":"Cancer"},{"key":"BFleu2013253_CR4","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bbmt.2012.08.021","volume":"19","author":"A Tanguy-Schmidt","year":"2013","unstructured":"Tanguy-Schmidt A, Rousselot P, Chalandon Y, Cayuela JM, Hayette S, Vekemans MC et al. Long-term follow-up of the imatinib GRAAPH-2003 Study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL Study. Biol Blood Marrow Transplant 2013; 19: 150\u2013155.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2013253_CR5","doi-asserted-by":"publisher","first-page":"4489","DOI":"10.1182\/blood-2009-01-199380","volume":"113","author":"AK Fielding","year":"2009","unstructured":"Fielding AK, Rowe JM, Richards SM, Buck G, Moorman AV, Durrant IJ et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII\/ECOG2993. Blood 2009; 113: 4489\u20134496.","journal-title":"Blood"},{"key":"BFleu2013253_CR6","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1182\/blood-2002-03-0704","volume":"100","author":"H Dombret","year":"2002","unstructured":"Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia\u2014results of the prospective multicenter LALA-94 trial. Blood 2002; 100: 2357\u20132366.","journal-title":"Blood"},{"key":"BFleu2013253_CR7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1182\/blood-2008-03-143115","volume":"112","author":"GG Laport","year":"2008","unstructured":"Laport GG, Alvarnas JC, Palmer JM, Snyder DS, Slovak ML, Cherry AM et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood 2008; 112: 903\u2013909.","journal-title":"Blood"},{"key":"BFleu2013253_CR8","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1182\/blood-2003-10-3560","volume":"104","author":"M Hunault","year":"2004","unstructured":"Hunault M, Harousseau JL, Delain M, Truchen-Graczyk M, Cahn JY, Witz F et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004; 104: 3028\u20133037.","journal-title":"Blood"},{"key":"BFleu2013253_CR9","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1182\/blood-2003-08-2958","volume":"103","author":"DA Thomas","year":"2004","unstructured":"Thomas DA, Faderl S, Cortes J, O\u2019Brien S, Giles FJ, Kornblau SM et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103: 4396\u20134407.","journal-title":"Blood"},{"key":"BFleu2013253_CR10","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1182\/blood-2006-03-011908","volume":"109","author":"A de Labarthe","year":"2007","unstructured":"de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007; 109: 1408\u20131413.","journal-title":"Blood"},{"key":"BFleu2013253_CR11","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3324\/haematol.2009.011221","volume":"95","author":"JM Ribera","year":"2010","unstructured":"Ribera JM, Oriol A, Gonzalez M, Vidriales B, Brunet S, Esteve J et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica 2010; 95: 87\u201395.","journal-title":"Haematologica"},{"key":"BFleu2013253_CR12","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1002\/cncr.21932","volume":"106","author":"M Yanada","year":"2006","unstructured":"Yanada M, Matsuo K, Suzuki T, Naoe T . Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer 2006; 106: 2657\u20132663.","journal-title":"Cancer"},{"key":"BFleu2013253_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1182\/blood-2004-05-1746","volume":"106","author":"B Wassmann","year":"2005","unstructured":"Wassmann B, Pfeifer H, Stadler M, Bornhauser M, Bug G, Scheuring UJ et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2005; 106: 458\u2013463.","journal-title":"Blood"},{"key":"BFleu2013253_CR14","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"AH Goldstone","year":"2008","unstructured":"Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation\/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII\/ECOG E2993). Blood 2008; 111: 1827\u20131833.","journal-title":"Blood"},{"key":"BFleu2013253_CR15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3324\/haematol.2011.040261","volume":"96","author":"R Ram","year":"2011","unstructured":"Ram R, Storb R, Sandmaier BM, Maloney DG, Woolfrey A, Flowers ME et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica 2011; 96: 1113\u20131120.","journal-title":"Haematologica"},{"key":"BFleu2013253_CR16","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/bmt.2012.261","volume":"48","author":"PG Medd","year":"2013","unstructured":"Medd PG, Peniket AJ, Littlewood TJ, Pearce R, Perry J, Kirkland KE et al. Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study. Bone Marrow Transplant 2013; 48: 982\u2013987.","journal-title":"Bone Marrow Transplant"},{"key":"BFleu2013253_CR17","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1038\/leu.2009.102","volume":"23","author":"BS Cho","year":"2009","unstructured":"Cho BS, Lee S, Kim YJ, Chung NG, Eom KS, Kim HJ et al. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study. Leukemia 2009; 23: 1763\u20131770.","journal-title":"Leukemia"},{"key":"BFleu2013253_CR18","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.bbmt.2009.07.003","volume":"15","author":"AS Stein","year":"2009","unstructured":"Stein AS, Palmer JM, O\u2019Donnell MR, Kogut NM, Spielberger RT, Slovak ML et al. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant 2009; 15: 1407\u20131414.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2013253_CR19","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1182\/blood-2008-10-184093","volume":"113","author":"V Bachanova","year":"2009","unstructured":"Bachanova V, Verneris MR, DeFor T, Brunstein CG, Weisdorf DJ . Prolonged survival in adults with acute lymphoblastic leukemia after reduced-intensity conditioning with cord blood or sibling donor transplantation. Blood 2009; 113: 2902\u20132905.","journal-title":"Blood"},{"key":"BFleu2013253_CR20","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/blood-2010-01-264077","volume":"116","author":"DI Marks","year":"2010","unstructured":"Marks DI, Wang T, Perez WS, Antin JH, Copelan E, Gale RP et al. The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood 2010; 116: 366\u2013374.","journal-title":"Blood"},{"key":"BFleu2013253_CR21","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1182\/blood-2010-02-266551","volume":"116","author":"M Mohty","year":"2010","unstructured":"Mohty M, Labopin M, Volin L, Gratwohl A, Socie G, Esteve J et al. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation. Blood 2010; 116: 4439\u20134443.","journal-title":"Blood"},{"key":"BFleu2013253_CR22","first-page":"1688","volume":"8","author":"JP Radich","year":"1994","unstructured":"Radich JP, Kopecky KJ, Boldt DH, Head D, Slovak ML, Babu R et al. Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction. Leukemia 1994; 8: 1688\u20131695.","journal-title":"Leukemia"},{"key":"BFleu2013253_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1046\/j.1365-2141.2003.03988.x","volume":"120","author":"S Lee","year":"2003","unstructured":"Lee S, Kim DW, Cho B, Kim YJ, Kim YL, Hwang JY et al. Risk factors for adults with Philadelphia-chromosome-positive acute lymphoblastic leukemia in remission treated with allogeneic bone marrow transplantation: the potential of real-time quantitative reverse-transcription polymerase chain reaction. Br J Haematol 2003; 120: 145\u2013153.","journal-title":"Br J Haematol"},{"key":"BFleu2013253_CR24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.2008.07377.x","volume":"143","author":"M Yanada","year":"2008","unstructured":"Yanada M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y et al. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy. Br J Haematol 2008; 143: 503\u2013510.","journal-title":"Br J Haematol"},{"key":"BFleu2013253_CR25","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/sj.leu.2403683","volume":"19","author":"F Pane","year":"2005","unstructured":"Pane F, Cimino G, Izzo B, Camera A, Vitale A, Quintarelli C et al. Significant reduction of the hybrid BCR\/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia 2005; 19: 628\u2013635.","journal-title":"Leukemia"},{"key":"BFleu2013253_CR26","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.bbmt.2008.04.003","volume":"14","author":"D Weisdorf","year":"2008","unstructured":"Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008; 14: 748\u2013758.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2013253_CR27","doi-asserted-by":"publisher","first-page":"3644","DOI":"10.1200\/JCO.2010.28.1287","volume":"28","author":"R Bassan","year":"2010","unstructured":"Bassan R, Rossi G, Pogliani EM, Di Bona E, Angelucci E, Cavattoni I et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09\/00. J Clin Oncol 2010; 28: 3644\u20133652.","journal-title":"J Clin Oncol"},{"key":"BFleu2013253_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367\u2013369.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2013253_CR29","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","volume":"18","author":"TA Gooley","year":"1999","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695\u2013706.","journal-title":"Stat Med"},{"key":"BFleu2013253_CR30","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912\u20132919.","journal-title":"Blood"},{"key":"BFleu2013253_CR31","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood-2006-10-052746","volume":"109","author":"M Vignetti","year":"2007","unstructured":"Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) LAL0201-B protocol. Blood 2007; 109: 3676\u20133678.","journal-title":"Blood"},{"key":"BFleu2013253_CR32","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/sj.leu.2404320","volume":"20","author":"A Delannoy","year":"2006","unstructured":"Delannoy A, Delabesse E, Lheritier V, Castaigne S, Rigal-Huguet F, Raffoux E et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia 2006; 20: 1526\u20131532.","journal-title":"Leukemia"},{"key":"BFleu2013253_CR33","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1182\/blood-2006-11-052373","volume":"110","author":"H Pfeifer","year":"2007","unstructured":"Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007; 110: 727\u2013734.","journal-title":"Blood"},{"key":"BFleu2013253_CR34","first-page":"1779","volume":"32","author":"K Watanabe","year":"2012","unstructured":"Watanabe K, Minami Y, Ozawa Y, Miyamura K, Naoe T . T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports. Anticancer Res 2012; 32: 1779\u20131783.","journal-title":"Anticancer Res"},{"key":"BFleu2013253_CR35","doi-asserted-by":"publisher","first-page":"6963","DOI":"10.1182\/blood-2011-01-332007","volume":"117","author":"RJ Soiffer","year":"2011","unstructured":"Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood 2011; 117: 6963\u20136970.","journal-title":"Blood"},{"key":"BFleu2013253_CR36","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1182\/blood-2009-06-230391","volume":"115","author":"G Riva","year":"2010","unstructured":"Riva G, Luppi M, Barozzi P, Quadrelli C, Basso S, Vallerini D et al. Emergence of BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph+ acute lymphoblastic leukemia during long-term imatinib mesylate treatment. Blood 2010; 115: 1512\u20131518.","journal-title":"Blood"},{"key":"BFleu2013253_CR37","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29: 2493\u20132498.","journal-title":"J Clin Oncol"},{"key":"BFleu2013253_CR38","doi-asserted-by":"publisher","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","volume":"118","author":"R Foa","year":"2011","unstructured":"Foa R, Vitale A, Vignetti M, Meloni G, Guarini A, De Propris MS et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2011; 118: 6521\u20136528.","journal-title":"Blood"},{"key":"BFleu2013253_CR39","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/leu.2012.324","volume":"27","author":"OG Ottmann","year":"2012","unstructured":"Ottmann OG, Larson RA, Kantarjian HM, le Coutre PD, Baccarani M, Hochhaus A et al. Phase II study of nilotinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2012; 27: 1411\u20131413.","journal-title":"Leukemia"},{"key":"BFleu2013253_CR40","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509\u20131518.","journal-title":"N Engl J Med"},{"key":"BFleu2013253_CR41","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","volume":"113","author":"R Bassan","year":"2009","unstructured":"Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood 2009; 113: 4153\u20134162.","journal-title":"Blood"},{"key":"BFleu2013253_CR42","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/leu.2012.352","volume":"27","author":"H Pfeifer","year":"2012","unstructured":"Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhauser M, Stadler M et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1 positive acute lymphoblastic leukemia. Leukemia 2012; 27: 1254\u20131262.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2013253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013253","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2013253.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:03:59Z","timestamp":1715951039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2013253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,30]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["BFleu2013253"],"URL":"https:\/\/doi.org\/10.1038\/leu.2013.253","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,30]]},"assertion":[{"value":"21 June 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}